Exclusive Webinar :Gain complete knowledge about how you can invest in global markets during an insightful webinar on April 16 at 11 am. Register Now!
you are here: HomeNewsIndia

India exports 50 million hydroxychloroquine tablets to US for COVID-19 fight: Source

The trade, India's biggest export of the drug to any country, follows a request by US President Donald Trump for New Delhi to release supplies of hydroxychloroquine as a possible treatment for the respiratory disease.

April 30, 2020 / 08:17 PM IST
Representative image

Representative image

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

India has shipped 50 million tablets of hydroxychloroquine to the United States, an Indian source with direct knowledge of the exports said, although US regulators warned the anti-malarial drug may have harmful side effects in the treatment of COVID-19.

The trade, India's biggest export of the drug to any country, follows a request by US President Donald Trump for New Delhi to release supplies of hydroxychloroquine as a possible treatment for the respiratory disease.

"It amounts to 50 million tablets... Commercial companies are pursuing. It's ongoing," said the source, who declined to be identified due to the sensitivity of discussions with the United States.

The US Food and Drug Administration, the European Union's drug regulator and the Canadian health department have cautioned against the use of hydroxychloroquine, citing side effects such as abnormal heart rhythms and a dangerously rapid heart rate.

However, the health warnings have done little to deter the drug's imports to the United States, where some doctors are continuing to prescribe the drug for the treatment of COVID-19.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"There is high demand for hydroxychloroquine in the international market including US," Viranchi Shah, senior vice-president, Indian Drug Manufacturers Association (IDMA), told Reuters.

This month India said it would allow some exports of hydroxychloroquine after Trump touted it as a "game changer" and urged Prime Minister Narendra Modi to send supplies.

In Modi's home state of Gujarat, 68 new licences have been issued to drugmakers to manufacture hydroxychloroquine formulations, HG Koshia, commissioner, Food and Drug Control Administration (FDCA), Gujarat, told Reuters.

"Majority of these licences are for exports," he said.

Teva Pharmaceutical Industries, IPCA Laboratories and Cadila Healthcare are among India's leading suppliers of hydroxychloroquine.

Cadila Healthcare recently said it was ramping up production tenfold to 30 metric tonnes per month.

Sales of the decades-old treatment had soared overnight after Trump's advocacy of the drug, raising questions whether political pressure had overridden scientific criteria in the crisis.

As the US coronavirus death toll topped 60,000 on Wednesday - the highest in the world - doctors in the United States are desperate for anything that might alter the course of the disease, which attacks the lungs and can shut down other organs in severe cases.

"Pharma companies in Gujarat are continuing to produce and export hydroxychloroquine in large quantities," IDMA's Shah said.

The foreign ministry said India was continuing to supply hydroxychloroquine, and other essential medicines produced in India, to other countries. These supplies were taking place both on a humanitarian and a commercial basis.

Follow our full coverage of the coronavirus pandemic here.
Reuters
first published: Apr 30, 2020 08:10 pm

stay updated

Get Daily News on your Browser
Sections